Scholarlink

<p>Uncontrolled proliferation, resistance to apoptosis, inability to maintain genome integrity, and, recently, epigenetic reprogramming are all hallmarks of cancer. A number of gene expression and cell signaling networks control these-often-interconnected processes, while the study of their deregulation is in the forefront of cancer research for decades. Here we present data from cells and patients indicating that KMT2C, one of the most frequently mutated proteins in solid malignancies, is involved in all these processes. Its loss, a bad prognosis marker in bladder cancer, is associated with activation of the PI3K/PDK/AKT oncogenic/antiapoptotic axis, and tolerance to DNA damage during cell cycle progression. On the other hand, these cells suffer from mitotic stress that can be therapeutically exploited. Treatment with a PLK1 inhibitor showed high efficacy in vivo, and was associated with mitotic catastrophe and cellular senescence, providing evidence that targeting genes that promote mitotic progression could be a promising therapeutic approach in the subset of tumors with KMT2C loss.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

KMT2C inactivation leads to PTEN downregulation and tolerance to DNA damage during cell cycle progression

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月28日

查看全文
  • Theodoros Rampias,
  • Andreas Goutas,
  • Dimitris Karagiannis,
  • Zoi Kanaki,
  • Antigoni Makri,
  • Lorena Hoxhallari,
  • Fotini E. Koukouzeli,
  • Varvara Paraskevopoulou,
  • Dimitra Tsouraki,
  • Nikolaos Paschalidis,
  • Margaritis Avgeris,
  • Andreas Scorilas,
  • Apostolos Klinakis

摘要

Uncontrolled proliferation, resistance to apoptosis, inability to maintain genome integrity, and, recently, epigenetic reprogramming are all hallmarks of cancer. A number of gene expression and cell signaling networks control these-often-interconnected processes, while the study of their deregulation is in the forefront of cancer research for decades. Here we present data from cells and patients indicating that KMT2C, one of the most frequently mutated proteins in solid malignancies, is involved in all these processes. Its loss, a bad prognosis marker in bladder cancer, is associated with activation of the PI3K/PDK/AKT oncogenic/antiapoptotic axis, and tolerance to DNA damage during cell cycle progression. On the other hand, these cells suffer from mitotic stress that can be therapeutically exploited. Treatment with a PLK1 inhibitor showed high efficacy in vivo, and was associated with mitotic catastrophe and cellular senescence, providing evidence that targeting genes that promote mitotic progression could be a promising therapeutic approach in the subset of tumors with KMT2C loss.